阿替普酶和尿激酶对缺血性脑卒中患者血清S100β、HCY水平的影响观察

Observation on the Effects of Alteplase and Urokinase on the Serum Levels of S100β and HCY in Patients with Ischemic Stroke

目的观察阿替普酶和尿激酶对缺血性脑卒中患者血清S100β蛋白(S100β)、同型半胱氨酸(HCY)水平的影响。方法 90例缺血性脑卒中患者随机分为两组各45例,实验组采用阿替普酶溶栓治疗,对照组采用尿激酶溶栓治疗,比较两组的总有效率、 NIHSS评分以及血清S100β、 HCY水平。结果实验组的总有效率显著高于对照组(P <0.05);治疗14 d后,两组患者的NIHSS评分与血清S100β、 HCY水平均显著低于治疗前,且实验组各指标均显著低于对照组(均P <0.05)。结论阿替普酶在缺血性脑卒中的治疗中,相比尿激酶治疗有更好的疗效,可显著降低血清S100β、 HCY水平,有效地减少神经功能损伤。

Objective To observe the effects of alteplase and urokinase on the serum levels of S 100β and HCY in patients with ischemic stroke. Methods 90 cases of patients with ischemic stroke were randomly divided into two groups equally. The experimental group was treated with alteplase for thrombolysis, while the control group was treated with urokinase for thrombolysis. The total effective rate of treatment, NIHSS score, and serum levels of S 100β and HCY were compared between the two groups. Results The total effective rate of the experimental group was significantly higher than that of the control group （P 〈0.05）; After 14 d of treatment, both groups had significantly decreased NIHSS score, and serum levels of S100β and HCY compared with those before treatment, and the indicators of the experimental group were significantly lower than those of the control group （all P〈0.05）. Conclusions Alteplase has better efficacy than urokinase in the treatment of ischemic stroke, which can significantly reduce the serum levels of S100β and HCY, and effectively reduce the neurological deficit.